Neuren Pharmaceuticals Gains AU$50 millions from PRV Sale to Boost Pipeline Development

Neuren Pharmaceuticals Limited (ASX: NEU) is set to receive around AU$50 million from the sale of a Rare Pediatric Disease Priority Review Voucher (PRV) by its U.S. partner, Acadia Pharmaceuticals (NASDAQ: ACAD). The PRV, issued by the U.S. Food and Drug Administration (FDA) following approval of DAYBUE (trofinetide) for treating Rett syndrome, was sold for $150 million, with Neuren entitled to a one-third share. Rett syndrome is a rare neurodevelopmental disorder primarily affecting females, with DAYBUE offering symptom relief by targeting inflammatory and neurodevelopmental pathways. This substantial payout will support Neuren's continued investment in its neurodevelopmental drug pipeline, according to CEO Jon Pilcher. At the time of writing, Neuren’s shares are trading at $12.98, marking a 5.8% gain.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com